Here is the design of a clinical trial:

Official Title: Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases

Included conditions:
- Neuroendocrine Tumors
- Liver Metastases

Study Armgroups:
- {'label': 'Intra-arterially treated liver lobe', 'type': 'EXPERIMENTAL', 'description': 'Depending on the allocation after randomization, Lu-177-dotatate will be infused in either the left or the right hepatic artery, following catheterization using the Seldinger-technique.', 'interventionNames': ['Drug: Lutetium Lu 177-DOTATATE']}
- {'label': "'Intravenously' treated liver lobe", 'type': 'ACTIVE_COMPARATOR', 'description': 'The lobe that is not treated intra-arterially, will act as the intravenously treated lobe, due to the first-pass effect.', 'interventionNames': ['Drug: Lutetium Lu 177-DOTATATE']}

Interventions:
- {'type': 'DRUG', 'name': 'Lutetium Lu 177-DOTATATE', 'description': 'Intra-arterial infusion of Lu-177-DOTATATE', 'armGroupLabels': ["'Intravenously' treated liver lobe", 'Intra-arterially treated liver lobe'], 'otherNames': ['Lutathera']}

Primary Outcomes:
- {'measure': 'The difference in post-treatment tumor-to-non-tumor (T/N) activity concentration ratio on SPECT/CT between the intra-arterial treated liver lobe and the intravenous treated liver lobe.', 'description': 'To assess if there is a difference in post-treatment tumor-to-non-tumor (T/N) activity concentration ratio on SPECT/CT between the intra-arterial treated liver lobe and the intravenous treated liver lobe. The T/N activity concentration will be measured on SPECT/CT. The primary endpoint will be assessed after the first treatment cycle. For each liver lobe up to three tumors (i.e. all \\>3 cm) will be selected based on size (i.e. the largest lesions without central necrosis). The weighted average activity per voxel of these lesions will be divided by the normal liver tissue mean activity per voxel (i.e. a VOI with 3 cm diameter will be placed in the normal liver tissue) to calculate the T/N ratio. The T/N activity ratios of the second, third, and final treatment cycle will be assessed as secondary endpoint. Intra- and inter-patient differences will be studied.', 'timeFrame': '24 hours'}

Please estimate the sample size based on the assumption: 
One-sided significance level (α) of 0.025, power of approximately 0.9, using a sequential testing procedure with an O'Brien-Fleming type error spending function, and futility boundary values of T1 = -0.1045056 and T2 = 2.045732
Sample size assessment
        The intended sample size is calculated using a paired samples t test on the difference in T/N uptake ratio between the IA-treated and contralateral lobes, which is equivalent to a one-sample t test on the within-patient difference scores. Assuming a moderate to large effect (i.e., \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\text{d}_{z}={\mu}_{diff}/{\sigma}_{diff}= 0.65  $$\end{document}Cohen'sdz=Î¼diff/Ïdiff=0.65), a one-sided Î± of 0.025, and using a sequential testing procedure with an OâBrien-Fleming type error spending function, a power of approximately 0.9 is obtained with futility boundary values equal to T1Â =âââ0.1045056 and T2Â =â2.045732 for an interim analysis at n1Â =â10 and final analysis at n2Â =â26. Interim analysis will therefore be performed after ten patients have been treated, and final analysis will be performed after 26 patients have been treated.